Pharmacovigilance
| Product | Date | Safety information | Attachments |
|---|---|---|---|
| Cilest® - Ethinylestradiol, Norgestimate |
The reason for the recall is that dissolution testing of norgestimate. |
||
| TYKERB® - Lapatinib |
Comparative data have shown that Lapatinib based regimens are less effective than trastuzumab based regimens in certain settings. |
||
| Plavix® - Clopidogrel |
Regarding Bleeding Risk with Plavix in Atrial Fibrillation Patients. |
||
| Curacne® - Isotretinoin |
Pregnancy Prevention Program |
||
| ROACCUTANE®- Isotretinoin |
Pregnancy Prevention Program |
||
| Tysabri® - Connect |
Risk of progressive multifocal leukoencephalopathy PML |
||
| Protelos® - Strontium ranelate |
Increased risk of myocardial infarction |
||
| Miacalcic® - Calcitonin |
increased risk of malignancies with long term calcitonin use |
||
| Solpadeine® - Paracetamol, Caffeine, Codeine Phosphate |
The use of codeine containing products for children after tonsillectomy and /or adenoidectomy surgery |
||
| Vastarel® - Trimetazidine |
Outcome of the Benefit-Risk Re-evaluation of Trimetazidine |
